Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) has appointed Dr. Freda Lewis-Hall, DFAPA, MFPM, to its board of directors, where she will also serve as chair of the company’s Scientific Advisory Committee, subject to approval by Cboe Canada. Dr. Lewis-Hall brings more than 40 years of experience across clinical care, research, academia and senior biopharmaceutical leadership, including more than a decade on Pfizer’s executive leadership team as executive vice president and chief medical officer, as well as leadership roles at Vertex Pharmaceuticals, Bristol Myers Squibb, Pharmacia Corporation and Eli Lilly and Company.
A Distinguished Fellow of the American Psychiatric Association and former advisor to the National Institute of Mental Health, Dr. Lewis-Hall will provide scientific, clinical and regulatory governance across Helus’ portfolio as the company advances its novel serotonergic agonist programs targeting serious mental health conditions. The appointment underscores Helus Pharma’s commitment to leveraging deep expertise to develop proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity.
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical stage pharmaceutical company focused on addressing the large unmet need for people who suffer from depression, anxiety, and other mental health conditions. The company is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004 is in Phase 2 for generalized anxiety disorder. Helus Pharma also has an extensive research portfolio of investigational NSAs.
The addition of Dr. Lewis-Hall to the board and as chair of the Scientific Advisory Committee is expected to strengthen Helus Pharma’s governance and strategic direction as it aims to improve the treatment landscape with durable mental health solutions. For more details, the full press release is available at https://ibn.fm/fcqsQ.
Helus Pharma operates in Canada, the United States, the United Kingdom and Ireland. Company updates and further information can be found at www.helus.com or by following the team on social media platforms.
